CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

In CRISPR gene editing, guide RNA (gRNA) directs the Cas9 complex to its target. Impurities introduced during gRNA synthesis ...

CRISPR-Cas9 has transformed the life sciences by giving researchers a seemingly simple tool for cutting DNA at chosen ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Most of any gains (or lack thereof) from here will be driven by just three factors.